
Tesamorelin 1kits (10Vials)
FOR LABORATORY RESEARCH USE ONLY
Peptide/API raw-material powder for qualified laboratory research and technical cooperation. Specification, packaging, MOQ, quotation and available documentation are confirmed per inquiry.
DISCLAIMER: This product is sold strictly for laboratory research purposes only. Not for human consumption, medical use, or veterinary use.
价格范围:$50.00 至 $300.00
DetailCustomer Reviews
Tesamorelin – Detailed Introduction & Benefits (English)
Basic Introduction
Tesamorelin (brand name: Egrifta SV) is a synthetic, stabilized analog of human Growth Hormone-Releasing Hormone (GHRH).
- Classification: 44‑amino‑acid peptide with an N‑terminal trans‑3‑hexenoic acid modification.
- Developer: Theratechnologies Inc. (Canada).
- FDA Approval: 2010, for reducing excess visceral abdominal fat in HIV‑infected adults with lipodystrophy.
- Key feature: Resists degradation by DPP‑IV, far more stable and potent than native GHRH.
- Administration: Subcutaneous injection (once daily).
- Half‑life: ~8–38 minutes; short‑acting but triggers robust, pulsatile GH release.
Mechanism of Action
- GHRH Receptor Agonist: Binds selectively to GHRH receptors on pituitary somatotroph cells.
- Natural GH Pulse: Stimulates synthesis and pulsatile release of endogenous GH, mimicking the body’s natural rhythm.
- IGF‑1 Elevation: GH drives liver and tissue production of IGF‑1, the key mediator of GH’s anabolic/lipolytic effects.
- Visceral Lipolysis: Activates hormone‑sensitive lipase (HSL) in adipocytes, preferentially breaking down visceral (abdominal) fat over subcutaneous fat.
- Preserves Feedback: Unlike exogenous HGH, it does not suppress the hypothalamic‑pituitary‑adrenal (HPA) axis; amplifies natural GH regulation.
Main Benefits
1. Reduction of Visceral Abdominal Fat (Primary Indication)
- FDA‑proven: Significantly reduces visceral adipose tissue (VAT) in HIV‑associated lipodystrophy.
- Targeted fat loss: Reduces dangerous belly fat linked to insulin resistance, metabolic syndrome, and cardiovascular risk.
- Body recomposition: Improves waist circumference and abdominal contour without muscle loss.
2. Growth Hormone & IGF‑1 Optimization
- Restores youthful GH pulsatility: Reverses age‑related GH/IGF‑1 decline (somatopause).
- Elevates IGF‑1: Boosts IGF‑1 levels to support metabolism, muscle, and tissue repair.
- Safe GH stimulation: Avoids supraphysiological GH spikes seen with direct HGH use.
3. Metabolic Health & Insulin Sensitivity
- Improves glucose regulation: Enhances insulin sensitivity and glucose uptake in peripheral tissuesNational Center for Biotechnology Information.
- Lowers triglycerides: Reduces hepatic lipogenesis and circulating triglyceride levels.
- Supports liver health: Reduces visceral fat and hepatic steatosis (fatty liver risk).
4. Lean Muscle & Physical Performance
- Anabolic support: Promotes muscle protein synthesis and preserves lean mass during fat loss.
- Strength & recovery: May improve exercise endurance, reduce fatigue, and accelerate muscle repair.
- Anti‑catabolic: Counters age‑related muscle wasting (sarcopenia).
5. Anti‑Aging & Longevity
- Cellular repair: Boosts IGF‑1‑mediated tissue regeneration and reduces senescence.
- Skin health: May improve elasticity, reduce fine lines, and enhance collagen synthesis.
- Energy & vitality: Enhances daily energy, mental clarity, and sleep quality.
6. Cardiovascular Protection
- Reduces cardiac risk: Targets visceral adiposity, a major driver of heart disease.
- Improves lipid profile: Lowers LDL (“bad” cholesterol) and raises HDL (“good” cholesterol).
- Endothelial support: May improve blood vessel function and reduce inflammation.
Key Advantages Over Other GHRPs/GHRHs
- Full‑length GHRH (1–44): More potent than truncated analogs (e.g., Sermorelin 1–29).
- DPP‑IV resistance: Longer half‑life and more consistent GH pulses.
- Visceral fat specificity: Superior for reducing abdominal/visceral fat vs. GHRP‑2/GHRP‑6.
- Minimal hunger: Unlike GHRP‑6, no significant appetite increase.
Common Off‑Label Uses
- General abdominal/visceral fat loss
- Anti‑aging & longevity protocols
- Body recomposition (preserve muscle, reduce fat)
- Metabolic syndrome/insulin resistance support
- Age‑related GH decline (somatopause)
Safety Note
- Contraindicated in pregnancy, active malignancy, and uncontrolled diabetes.
- May cause mild injection‑site reactions, headache, or joint pain (usually transient).
Research Use Only. This catalog information is reproduced from the customer legacy website. Products are not for human or veterinary use. Confirm current specification, availability and documentation before ordering.
